ALTERNATING CHEMORADIOTHERAPY WITH CISPLATIN AND 5-FLUOROURACIL PLUS BLEOMYCIN BY CONTINUOUS INFUSION FOR LOCALLY ADVANCED UNDIFFERENTIATED CARCINOMA NASOPHARYNGEAL TYPE

被引:38
作者
AZLI, N
ARMAND, JP
RAHAL, M
WIBAULT, P
BOUSSEN, H
ESCHWEGE, F
SCHWAAB, G
GASMI, J
BACHOUCHI, M
CVITKOVIC, E
机构
[1] INST GUSTAVE ROUSSY, UNITE LA GRANGE VILLEJUIF, F-77176 VILLEJUIF, FRANCE
[2] INST SALAH AZAIZ, TUNIS, TUNISIA
[3] CTR ANTI CANC BENBADIS, CONSTANTINE, ALGERIA
关键词
D O I
10.1016/0959-8049(92)90005-M
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
More than 80% of undifferentiated carcinoma nasopharyngeal type patients with N3 disease (AJC-UICC 1987) will die with or from distant metastases within 3 years after the first symptom. From February 1986 to November 1987 30 consecutive patients with very advanced local disease were entered in a programme with chemotherapy-radiotherapy (CT-RT) alternation after a thorough work-up to eliminate the possibility of distant metastases. Protocol: two cycles of cisplatin 100 mg/m2 day 1, bleomycin 15 mg intravenously day 1 and 16 mg/m2 per day by continuous infusion days 1-5; 5-fluorouracil (5-FU) 650 mg/m2 per day by continuous infusion days 1-5 4 weeks apart. This was followed by two series of high-energy radiotherapy, 35 Gy/3.5 weeks, with a third chemotherapy cycle in between. 27 men and 3 women were treated, the median age was 37 years (range 17-71) and the mean WHO performance status was 1 (range 0-3). TNM classification: 15 T4, 9 T3, 6 T2, 28 N3 and 2 N2c. 18 patients had nodes larger than 8 cm and 24 had bulky bilateral cervical nodes. Toxicity for this protocol was moderate, nausea and vomiting being the main side-effects. Results after two CT cycles were 3 complete responses (CR; 10%), 22 partial responses (PR; 73%), 2 disease stabilisations, 2 progressions, and 1 patient inevaluable. Of the 30 patients, 27 patients completed the CT-RT protocol, 2 patients died before radiotherapy and 1 refused treatment after 2 days on protocol. 25 patients were in CR 3 months after the end of radiotherapy. As of August 1991, with a median follow-up of 55 months (range 43-63), there are 17 patients alive, 2 of them with active disease and 15 are NED (2 after salvage therapy).
引用
收藏
页码:1792 / 1797
页数:6
相关论文
共 62 条
[11]  
2-C
[12]  
CHOKSI A, 1988, P AM SOC CLIN ONCOL, V588
[13]   IRRADIATION OF NASOPHARYNGEAL CARCINOMA - CORRELATIONS WITH TREATMENT FACTORS AND STAGE [J].
CHU, AM ;
FLYNN, MB ;
ACHINO, E ;
MENDOZA, EF ;
SCOTT, RM ;
JOSE, B .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1984, 10 (12) :2241-2249
[14]   NASOPHARYNGEAL CARCINOMA - THE DANA-FARBER CANCER INSTITUTE EXPERIENCE WITH 24 PATIENTS TREATED WITH INDUCTION CHEMOTHERAPY AND RADIOTHERAPY [J].
CLARK, JR ;
NORRIS, CM ;
DREYFUSS, AI ;
FALLON, BG ;
BALOGH, K ;
ANDERSON, RF ;
CHAFFEY, JT ;
ANDERSEN, JW ;
MILLER, D .
ANNALS OF OTOLOGY RHINOLOGY AND LARYNGOLOGY, 1987, 96 (05) :608-614
[15]  
CVITKOVIC E, 1989, CANC CHEMOTHERAPY CO, P175
[16]  
CVITKOVIC E, 1988, AM SOC CLIN ONCOL, V601
[17]  
CVITKOVIC E, 1987, P AM SOC CLIN ONCOL, V547
[18]  
DEHTE, 1983, EPSTEINBARR VIRUS NA, P43
[19]  
DETHE G, 1976, NASOPHARYNGAL CARCIN, P539
[20]  
DEXING Q, 1988, CANCER, V61, P1117